NAS:APVO (USA) Also trade in: Germany UK

Aptevo Therapeutics Inc

$ 0.87 -0.01 (-0.73%)
Volume: 849,215 Avg Vol (1m): 524,347
Market Cap $: 39.12 Mil Enterprise Value $: 21.80 Mil
P/E (TTM): 0.00 P/B: 0.56
Earnings Power Value 0
Net Current Asset Value 0.58
Tangible Book 1.24
Projected FCF 0
Median P/S Value 3.3
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.91
Cash-To-Debt range over the past 10 years
Min: 1.59, Med: 3.3, Max: 10000
Current: 1.91
1.59
10000
Equity-to-Asset 0.48
Equity-to-Asset range over the past 10 years
Min: 0.45, Med: 0.63, Max: 0.84
Current: 0.48
0.45
0.84
Debt-to-Equity 0.50
Debt-to-Equity range over the past 10 years
Min: 0.19, Med: 0.35, Max: 0.63
Current: 0.5
0.19
0.63
Debt-to-EBITDA -0.41
Debt-to-EBITDA range over the past 10 years
Min: -0.41, Med: -0.38, Max: -0.29
Current: -0.41
-0.41
-0.29
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.05
DISTRESS
GREY
SAFE
Beneish M-Score -1.83
Not Manipulator
Manipulator

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -190.65
Operating Margin range over the past 10 years
Min: -31385.29, Med: -296.02, Max: -112.84
Current: -190.65
-31385.29
-112.84
Net Margin % -199.29
Net Margin range over the past 10 years
Min: -31374.71, Med: -204.64, Max: 47.57
Current: -199.29
-31374.71
47.57
ROE % -108.96
ROE range over the past 10 years
Min: -161.53, Med: -95.5, Max: 10.52
Current: -108.96
-161.53
10.52
ROA % -62.10
ROA range over the past 10 years
Min: -102.37, Med: -58.2, Max: 6.68
Current: -62.1
-102.37
6.68
ROC (Joel Greenblatt) % -510.23
ROC (Joel Greenblatt) range over the past 10 years
Min: -918.05, Med: -703.38, Max: -366.18
Current: -510.23
-918.05
-366.18
3-Year Total Revenue Growth Rate -11.80
3-Year Revenue Growth Rate range over the past 10 years
Min: -33.2, Med: -15.5, Max: 279.8
Current: -15.5
-33.2
279.8
3-Year Total EBITDA Growth Rate 5.40
3-Year EBITDA Growth Rate range over the past 10 years
Min: -6.1, Med: 1.6, Max: 9.4
Current: 9.4
-6.1
9.4
3-Year EPS w/o NRI Growth Rate 7.10
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 7.1
Current: 7.1
0
7.1

» APVO's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:APVO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare HKSE:03839 XPAR:ALTHX ROCO:3205 TPE:1762 NAS:SPHS AMEX:NAVB WBO:MSBT AMEX:NBY ASX:BOT ASX:CPH NAS:INNT TSX:COM LSE:SCLP NAS:BCLI OSTO:ACTI LSE:OPTI NAS:AXSM XMCE:IKM XPAR:OSE ASX:ANR
Traded in other countries AP8.Germany 0HH3.UK
Address 2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a biosciences company. The company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline product includes Otlertuzumab, APVO414, ROR1 Candidate, Multiple ADAPTIR Candidates, ALG.APV-527, APVO436 and APVO210.

Ratios

Current vs industry vs history
PB Ratio 0.56
PB Ratio range over the past 10 years
Min: 0.44, Med: 0.86, Max: 2.67
Current: 0.56
0.44
2.67
PS Ratio 0.79
PS Ratio range over the past 10 years
Min: 0.65, Med: 3.02, Max: 7.41
Current: 0.79
0.65
7.41
EV-to-EBIT -0.43
EV-to-EBIT range over the past 10 years
Min: -1.9, Med: -0.2, Max: 0.7
Current: -0.43
-1.9
0.7
EV-to-EBITDA -0.45
EV-to-EBITDA range over the past 10 years
Min: -2, Med: -0.2, Max: 0.8
Current: -0.45
-2
0.8
EV-to-Revenue 0.77
EV-to-Revenue range over the past 10 years
Min: -2.7, Med: 0.7, Max: 5.1
Current: 0.77
-2.7
5.1
Current Ratio 3.15
Current Ratio range over the past 10 years
Min: 1.76, Med: 3.66, Max: 7.76
Current: 3.15
1.76
7.76
Quick Ratio 2.91
Quick Ratio range over the past 10 years
Min: 0.74, Med: 3.63, Max: 7.67
Current: 2.91
0.74
7.67
Days Inventory 78.91
Days Inventory range over the past 10 years
Min: 45.78, Med: 197.89, Max: 408.98
Current: 78.91
45.78
408.98
Days Sales Outstanding 81.38
Days Sales Outstanding range over the past 10 years
Min: 11.22, Med: 70.13, Max: 110.55
Current: 81.38
11.22
110.55
Days Payable 303.52
Days Payable range over the past 10 years
Min: 257.62, Med: 379.87, Max: 535.48
Current: 303.52
257.62
535.48

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -3.60
3-Year Share Buyback Rate range over the past 10 years
Min: -3.6, Med: -3, Max: -0.8
Current: -3.6
-3.6
-0.8

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 0.70
Price-to-Tangible-Book range over the past 10 years
Min: 0.55, Med: 1.15, Max: 2.99
Current: 0.7
0.55
2.99
Price-to-Median-PS-Value 0.26
Price-to-Median-PS-Value range over the past 10 years
Min: 0.25, Med: 1.04, Max: 2.06
Current: 0.26
0.25
2.06
Earnings Yield (Joel Greenblatt) % -231.60
Earnings Yield (Greenblatt) range over the past 10 years
Min: -20221.1, Med: -202.3, Max: 6513.3
Current: -231.6
-20221.1
6513.3

More Statistics

Revenue (TTM) (Mil) $ 26.02
EPS (TTM) $ -2.2
Beta 2.47
Volatility % 90.01
52-Week Range $ 0.67 - 5.8
Shares Outstanding (Mil) 45.09

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y